Pharmacogenomics in the clinic: genetic polymorphism contributing to venlafaxine-associated heart failure

Pharmacogenomics. 2019 Nov;20(17):1175-1178. doi: 10.2217/pgs-2019-0083.
No abstract available

Keywords: CYP polymorphism; CYP2D6; CYPC19; SNRI; Venlafaxine; antidepressants; drug induced cardiomyopathy; heart failure.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Azithromycin / administration & dosage
  • Azithromycin / adverse effects
  • Cytochrome P-450 CYP2C19 / genetics*
  • Cytochrome P-450 CYP2D6 / genetics*
  • Drug Interactions / genetics
  • Heart Failure / chemically induced
  • Heart Failure / drug therapy*
  • Heart Failure / genetics
  • Heart Failure / pathology
  • Humans
  • Male
  • Pharmacogenetics
  • Pneumonia / complications
  • Pneumonia / drug therapy
  • Polymorphism, Genetic / genetics
  • Venlafaxine Hydrochloride / administration & dosage*
  • Venlafaxine Hydrochloride / adverse effects

Substances

  • Venlafaxine Hydrochloride
  • Azithromycin
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP2D6